Endocrinology, Vol 124, 3003-3009, Copyright © 1989 by Endocrine Society

ARTICLES

Tissue-specific differences in the levels of proglucagon-derived peptides in streptozotocin-induced diabetes

PL Brubaker, DC So and DJ Drucker
Department of Physiology, University of Toronto, Ontario, Canada.

The synthesis and secretion of proglucagon-derived peptides are regulated in a tissue-specific manner in pancreas, intestine, and brain. We have examined the plasma and tissue levels of these peptides during the first 3 weeks of streptozotocin (STZ)-induced diabetes in the rat. Plasma glucose levels were markedly elevated (P less than 0.0001) within 24 h of STZ administration. The plasma levels of glucagon-like immunoreactive (GLI) peptides were significantly elevated on days 8-22 of diabetes (P less than 0.05-0.001). Ileal GLI peptide concentrations rose in parallel with the plasma levels (r = 0.39; P less than 0.006) to 250% of control levels (P less than 0.001); however, pancreatic GLI peptide content increased only transiently on day 1 (P less than 0.05). No significant differences in the posttranslational processing of proglucagon in normal or diabetic rats could be detected. The increment in ileal GLI peptide content was not associated with increases in intestinal proglucagon mRNA transcripts. In contrast, pancreatic, but not intestinal, somatostatin mRNA levels were increased on day 22 of diabetes. Diabetic rats were found to have small but significant changes in GLI and immunoreactive glucagon peptide content of the hypothalamus and medulla oblongata (P less than 0.05). These observations suggest that STZ-induced diabetes may produce tissue-specific perturbations in the biosynthesis and secretion of the proglucagon-derived peptides.

This article has been cited by other articles:

				J. W. Joseph, V. Koshkin, M. C. Saleh, W. I. Sivitz, C.-Y. Zhang, B. B. Lowell, C. B. Chan, and M. B. Wheeler Free Fatty Acid-induced {beta}-Cell Defects Are Dependent on Uncoupling Protein 2 Expression J. Biol. Chem., December 3, 2004; 279(49): 51049 - 51056. [Abstract] [Full Text] [PDF]

				J. W. Joseph, V. Koshkin, C.-Y. Zhang, J. Wang, B. B. Lowell, C. B. Chan, and M. B. Wheeler Uncoupling Protein 2 Knockout Mice Have Enhanced Insulin Secretory Capacity After a High-Fat Diet Diabetes, November 1, 2002; 51(11): 3211 - 3219. [Abstract] [Full Text] [PDF]

				T. J. Kieffer and J. Francis Habener The Glucagon-Like Peptides Endocr. Rev., December 1, 1999; 20(6): 876 - 913. [Abstract] [Full Text]

				E. Dumonteil, C. Magnan, B. Ritz-Laser, P. Meda, P. Dussoix, M. Gilbert, A. Ktorza, and J. Philippe Insulin, But Not Glucose Lowering Corrects the Hyperglucagonemia and Increased Proglucagon Messenger Ribonucleic Acid Levels Observed in Insulinopenic Diabetes Endocrinology, November 1, 1998; 139(11): 4540 - 4546. [Abstract] [Full Text] [PDF]

				P. L. Brubaker, A. Crivici, A. Izzo, P. Ehrlich, C.-H. Tsai, and D. J. Drucker Circulating and Tissue Forms of the Intestinal Growth Factor, Glucagon-Like Peptide-2 Endocrinology, November 1, 1997; 138(11): 4837 - 4843. [Abstract] [Full Text] [PDF]

				K. D. Fischer, S. Dhanvantari, D. J. Drucker, and P. L. Brubaker Intestinal growth is associated with elevated levels of glucagon-like peptide 2 in diabetic rats Am J Physiol Endocrinol Metab, October 1, 1997; 273(4): E815 - E820. [Abstract] [Full Text] [PDF]